Study drug for relapsed mantle cell lymphoma after BTK inhibitor
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 2 trial studies whether adding polatuzumab vedotin and rituximab to bendamustine (a chemotherapy combination) can help people with mantle cell lymphoma that has come back or is not responding after a BTK inhibitor (like ibrutinib, acalabrutinib, or zanubrutinib). If you qualify, you’ll be checked carefully to make sure your body can safely handle the treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have mantle cell lymphoma that has come back or didn’t respond after a BTK inhibitor medicine
- You’re an adult (age 18–80) and can give written consent
- You must have tumor tissue available from the relapse (or stored tissue blocks if re-biopsy isn’t possible)
- You need a recent bone marrow test (trephine biopsy) with flow cytometry within 8 weeks
- Your general health and blood counts must be good enough for treatment (with a few exceptions for lymphoma-related causes)
- You must not be pregnant or breastfeeding, and you must use reliable birth control or abstinence as required
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests how well polatuzumab combined with bendamustine and rituximab works for mantle cell lymphoma that has come back or not responded. It may help shrink tumors and improve disease control, especially after prior treatment with ibrutinib.
This Phase 2 trial tests how well two anti-cancer medicines—glofitamab and pirtobrutinib—work for mantle cell lymphoma (MCL) that has not responded well to prior BTK inhibitor therapy. It may help by shrinking the lymphoma after earlier treatment and checking how safe the combination is for people with similar disease history.
This Phase 2 trial tests how well the combination of pirtobrutinib and venetoclax works for people with mantle cell lymphoma that has come back or did not respond to treatment. It’s meant to help shrink the lymphoma and improve outcomes after prior therapies.
This trial tests a new combination of two targeted drugs (pacritinib plus a BTK inhibitor like ibrutinib) for people with mantle cell lymphoma that has come back or stopped responding to treatment. It may help if your current BTK inhibitor is no longer working well.
This trial tests a two-step treatment for people with a fast-growing form of mantle cell lymphoma (MCL). First, you take a daily pill (BTKi) plus an infusion (rituximab), then a newer targeted therapy (glofitamab) to try to make the response last. The goal is to shrink the cancer and keep it away.
This trial tests a combination of two targeted drugs for people with mantle cell lymphoma that has come back or stopped responding after prior treatment with a BTK inhibitor. The goal is to see if this new combination can effectively shrink tumors.
Hear when a new Lymphoma, Mantle-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.